Stocktoria
Vera Therapeutics, Inc. VERA
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2021-05-14
Vera Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $215.3M | $126.2M | $78.2M | $69.0M | $22.5M |
| Operating income | -$315.5M | -$167.2M | -$102.0M | -$90.9M | -$34.4M |
| Interest expense | — | — | $3.8M | $992,000 | $20,000 |
| Income tax | $1,000 | $1,000 | $1,000 | $1,000 | $1,000 |
| Net income | -$299.6M | -$152.1M | -$96.0M | -$89.1M | -$32.6M |
| EPS (diluted) | $-4.66 | $-2.75 | $-2.25 | $-3.35 | $-2.43 |
| Operating cash flow | -$241.1M | -$134.7M | -$92.2M | -$67.6M | -$23.7M |
| Free cash flow | -$241.7M | -$135.7M | -$92.2M | -$67.7M | -$23.7M |
| Cash & equivalents | $354.7M | $92.6M | $45.7M | $43.5M | $79.7M |
| Total assets | $734.7M | $655.7M | $175.5M | $131.4M | $83.7M |
| Total liabilities | $130.2M | $78.5M | $73.9M | $54.5M | $14.2M |
| Shareholders' equity | $604.5M | $577.2M | $101.7M | $76.9M | $69.6M |
Source: SEC EDGAR filings · CIK 0001831828 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.